Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the successful submission of a Phase Ⅰ Clinical Trial Application (CTA) in EU for RBD3133, a novel siRNA therapeutic targeting INHBE (inhibin subunit beta E), with overweight and obesity as its intended future therapeutic indications.

Obesity has become one of the world's most significant public health challenges, affecting more than one billion people globally and contributing to a substantial burden of type 2 diabetes, cardiovascular disease, and other obesity-related comorbidities. Despite recent advances in obesity treatment, there remains a significant need for innovative therapies that address the underlying biology of metabolic dysfunction and provide durable clinical benefit.

RBD3133 is designed to selectively silence INHBE, a gene encoding the protein activin E. Human genetic studies have demonstrated that individuals carrying naturally occurring loss-of-function variants in INHBE exhibit healthier fat distribution, improved metabolic characteristics, and lower estimated risk of coronary heart disease and type 2 diabetes. These findings support INHBE as a promising therapeutic target for obesity and related metabolic diseases.

The Phase Ⅰ study is a randomized, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered RBD3133 in participants with overweight or obesity. The trial will provide the first assessment of RBD3133 in humans and will establish the foundation for further clinical development.

"This CTA submission represents another clear step forward for our cardiometabolic pipeline and highlights our ability to translate compelling human genetic evidence into innovative RNAi medicines." said Dr. Anders Gabrielsen, Chief Medical Officer of Ribo.

The RBD3133 represents a pivotal step of Ribo's siRNA development portfolio in the field of cardiovascular and metabolic disease and is poised to serve as a cornerstone drug for the treatment of weight-loss-related cardiovascular and metabolic disorders. As Ribo's first candidate drug in the obesity therapeutic area, RBD3133 reflects the company's strategic focus on developing innovative medicines for large patient populations with substantial unmet medical need.